New Risk Score Predicts Infection Risk in Autoimmune Patients on Steroids

A new scoring system promises to better identify patients undergoing high-dose steroid treatment who are at increased risk of serious infections. The tool, designed for individuals with autoimmune inflammatory rheumatic diseases, aims to assist clinicians stratify risk and potentially adjust treatment plans accordingly. This development arrives as clinicians continue to balance the powerful anti-inflammatory benefits of glucocorticoids with their well-documented immunosuppressive effects.

Glucocorticoids: A Double-Edged Sword

Glucocorticoids, often referred to as steroids, are a mainstay in managing a wide range of autoimmune and inflammatory conditions. These medications work by suppressing the immune system, reducing inflammation and alleviating symptoms. Conditions like rheumatoid arthritis, lupus, and vasculitis frequently rely on glucocorticoid therapy for symptom control. However, this very immune suppression leaves patients vulnerable to opportunistic infections – infections that typically don’t affect people with healthy immune systems. Research published in Frontiers in Immunology highlights the inherent trade-off: while long-term, high-dose glucocorticoid therapy provides necessary relief, it carries the risk of significant adverse effects, including increased susceptibility to infection.

The challenge for clinicians has always been determining which patients are at the highest risk. Previously, risk assessment relied on a combination of clinical judgment and general risk factors, often leading to a broad-spectrum approach to infection prevention. This new scoring system offers a more targeted approach.

How the New Risk Tool Works

Details about the specific components of the scoring system are limited in the initial report from Medscape Medical News. However, the core principle is to identify patients who are likely to experience a heightened infection risk following high-dose glucocorticoid therapy. The system effectively categorizes patients into high- and low-risk groups, allowing for more tailored preventative strategies. It’s important to note that This represents a stratification tool, not a definitive predictor of infection; it provides a probability assessment to inform clinical decision-making.

Beyond Rheumatology: Targeted Glucocorticoid Delivery

The need for more refined risk assessment and mitigation strategies is underscored by ongoing research into alternative glucocorticoid delivery methods. Traditional systemic administration exposes the entire body to the drug, increasing the risk of widespread side effects. Recent advances, as presented at the Annals of the Rheumatic Diseases conference in June 2025, explore the use of antibody-drug conjugates (ADCs) to deliver glucocorticoids directly to immune cells.

This targeted approach, utilizing an ADC called LFD-200 that binds to the VISTA protein found on immune cells, aims to maximize therapeutic efficacy while minimizing systemic toxicity. By concentrating the drug at the site of inflammation, researchers hope to reduce the overall dose required and, lower the risk of infection. The VISTA protein’s rapid internalization is too intended to increase potency and provide sustained immune exposure.

Understanding Infection Risk in Context

It’s crucial to understand that even without high-dose steroid use, individuals with autoimmune inflammatory rheumatic diseases already have a somewhat increased risk of infection due to the underlying condition itself and the potential use of other immunosuppressant medications. The new scoring system aims to identify those patients for whom the addition of high-dose glucocorticoids significantly elevates that risk.

Absolute risk versus relative risk is also important. A relative risk increase might sound alarming, but the absolute risk may still be low. For example, a doubling of risk from 1% to 2% is a 100% relative increase, but the overall probability of infection remains small. Clinicians will need to interpret the scoring system’s output in light of each patient’s individual baseline risk factors.

What Happens Next: Implementation and Further Research

The next steps involve widespread clinical implementation and validation of the new scoring system. This will likely involve prospective studies to assess its accuracy in predicting infection risk across diverse patient populations and healthcare settings. Researchers will also need to refine the tool based on real-world data, potentially incorporating additional biomarkers or clinical variables to improve its predictive power.

ongoing research into targeted glucocorticoid delivery methods, like the LFD-200 ADC, holds promise for reducing the need for high-dose systemic therapy altogether. Clinical trials will be essential to evaluate the safety and efficacy of these novel approaches. The development of more precise risk assessment tools and targeted therapies represents a significant step forward in optimizing the management of autoimmune inflammatory rheumatic diseases, allowing clinicians to provide effective treatment while minimizing the risk of potentially life-threatening infections.

Patients currently on high-dose glucocorticoids should continue to follow their healthcare provider’s recommendations regarding infection prevention, including vaccinations and monitoring for signs of illness. Regular communication with a qualified clinician is essential for managing these complex conditions and ensuring the best possible outcomes.